ID   IIICF/c
AC   CVCL_4415
SY   III-CF/c; III-CF culture C
DR   Wikidata; Q54897435
RX   CelloPub=CLPUB00712;
RX   PubMed=7651392;
RX   PubMed=9175740;
RX   PubMed=19468068;
RX   PubMed=19935656;
RX   PubMed=22829774;
CC   Characteristics: Cell line positive for alternative lengthening of telomeres (ALT+) (CelloPub=CLPUB00712; PubMed=19935656).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Thr125Thr (c.375G>A); ClinVar=VCV000177825; Zygosity=Hemizygous; Note=Impairs TP53 splicing dramatically (from parent cell line).
CC   Caution: Was briefly displayed in Cell Bank Australia under catalog number CBA-0039 but was never intended to be distributed.
CC   Derived from site: In situ; Breast, stroma; UBERON=UBERON_0003584.
DI   NCIt; C3476; Li-Fraumeni syndrome
DI   ORDO; Orphanet_524; Li-Fraumeni syndrome
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_ZT89 ! IIICF
SX   Female
AG   30-40Y
CA   Spontaneously immortalized cell line
DT   Created: 04-04-12; Last updated: 29-06-23; Version: 14
//
RX   CelloPub=CLPUB00712;
RA   Henson J.D.;
RT   "The role of alternative lengthening of telomeres in human cancer.";
RL   Thesis PhD (2006), University of Sydney, Australia.
//
RX   PubMed=7651392; DOI=10.1128/mcb.15.9.4745;
RA   Rogan E.M., Bryan T.M., Hukku B., MacLean K., Chang A.C.-M., Moy E.L.,
RA   Englezou A., Warneford S.G., Dalla-Pozza L., Reddel R.R.;
RT   "Alterations in p53 and p16INK4 expression and telomere length during
RT   spontaneous immortalization of Li-Fraumeni syndrome fibroblasts.";
RL   Mol. Cell. Biol. 15:4745-4753(1995).
//
RX   PubMed=9175740; DOI=10.1093/hmg/6.6.921;
RA   Bryan T.M., Marusic L., Bacchetti S., Namba M., Reddel R.R.;
RT   "The telomere lengthening mechanism in telomerase-negative immortal
RT   human cells does not involve the telomerase RNA subunit.";
RL   Hum. Mol. Genet. 6:921-926(1997).
//
RX   PubMed=19468068; DOI=10.1083/jcb.200810084;
RA   Jiang W.-Q., Zhong Z.-H., Nguyen A., Henson J.D., Toouli C.D.,
RA   Braithwaite A.W., Reddel R.R.;
RT   "Induction of alternative lengthening of telomeres-associated PML
RT   bodies by p53/p21 requires HP1 proteins.";
RL   J. Cell Biol. 185:797-810(2009).
//
RX   PubMed=19935656; DOI=10.1038/nbt.1587;
RA   Henson J.D., Cao Y., Huschtscha L.I., Chang A.C.-M., Au A.Y.M.,
RA   Pickett H.A., Reddel R.R.;
RT   "DNA C-circles are specific and quantifiable markers of
RT   alternative-lengthening-of-telomeres activity.";
RL   Nat. Biotechnol. 27:1181-1185(2009).
//
RX   PubMed=22829774; DOI=10.1371/journal.pgen.1002772;
RA   Lovejoy C.A., Li W.-D., Reisenweber S., Thongthip S., Bruno J.,
RA   de Lange T., De S., Petrini J.H.J., Sung P.A., Jasin M., Rosenbluh J.,
RA   Zwang Y., Weir B.A., Hatton C., Ivanova E.V., MacConaill L.E., Hanna M.,
RA   Hahn W.C., Lue N.F., Reddel R.R., Jiao Y.-C., Kinzler K.W.,
RA   Vogelstein B., Papadopoulos N., Meeker A.K.;
RT   "Loss of ATRX, genome instability, and an altered DNA damage response
RT   are hallmarks of the alternative lengthening of telomeres pathway.";
RL   PLoS Genet. 8:E1002772-E1002772(2012).
//